In a year riddled with obstacles and adverse events, mersana therapeutics finally has some good news: The failure of mersana therapeutics’ lead ovarian cancer drug in a phase 1/2 trial has sent the biotech into a tailspin, resulting in layoffs affecting half of the employees in an. Downsizing related discussion, postings, questions and answers.
Mersana股价跌59：NaPi2b ADC严重出血事件导致临床入组暂停 Armstrong 2023年6月15日，Mersana
Mersana therapeutics (mrsn) shares nosedived 73% on thursday, from $3.91 to $1.07, after the company announced a 50% workforce reduction—more than 100 jobs, based.
It’s been a trying 2023 for mersana therapeutics and the year doesn’t appear to be ending on a high note.
The failure of mersana therapeutics’ lead ovarian cancer drug in a phase 1/2 trial has sent the biotech into a tailspin, resulting in layoffs affecting half of the employees in an. (july 27, 2023) the worker adjustment and retraining notification (warn) act requires employers with 100 or more employees to provide 60. Mersana therapeutics is down 78% in thursday trading after announcing that a pivotal trial for lead candidate upifitamab rilsodotin (upri) for ovarian cancer missed its. This time, mersana therapeutics' cancer drug has been slapped with a clinical hold after a patient in the therapy’s first trial died.
Mrsn) laid off fully half of its workforce in the wake of a surprise trial failure. The fda has lifted a clinical hold on a phase 1 trial for the antibody. In april, genocea biosciences ’ phase i/iia titan. The failure of the biotech's lead ovarian cancer drug in a phase 1/2 trial has prompted layoffs for half of the company's workforce.
Food and drug administration (fda) had paused enrollment in two studies of its ovarian cancer drug after five deaths in.
Mersana therapeutics said on thursday the u.s.
